- Home
- RHI vs VKTX Comparison
RHI vs VKTX Comparison
Compare RHI & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHI
- VKTX
- Stock Information
- Founded
- RHI 1948
- VKTX 2012
- Country
- RHI United States
- VKTX United States
- Employees
- RHI N/A
- VKTX N/A
- Industry
- RHI Professional Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RHI Consumer Discretionary
- VKTX Health Care
- Exchange
- RHI Nasdaq
- VKTX Nasdaq
- Market Cap
- RHI 3.7B
- VKTX 3.5B
- IPO Year
- RHI N/A
- VKTX 2015
- Fundamental
- Price
- RHI $37.17
- VKTX $27.05
- Analyst Decision
- RHI Hold
- VKTX Strong Buy
- Analyst Count
- RHI 5
- VKTX 13
- Target Price
- RHI $49.80
- VKTX $86.92
- AVG Volume (30 Days)
- RHI 1.8M
- VKTX 9.7M
- Earning Date
- RHI 10-21-2025
- VKTX 10-22-2025
- Dividend Yield
- RHI 6.34%
- VKTX N/A
- EPS Growth
- RHI N/A
- VKTX N/A
- EPS
- RHI 1.75
- VKTX N/A
- Revenue
- RHI $5,569,026,000.00
- VKTX N/A
- Revenue This Year
- RHI N/A
- VKTX N/A
- Revenue Next Year
- RHI $3.32
- VKTX N/A
- P/E Ratio
- RHI $21.22
- VKTX N/A
- Revenue Growth
- RHI N/A
- VKTX N/A
- 52 Week Low
- RHI $33.18
- VKTX $18.92
- 52 Week High
- RHI $78.41
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- RHI 46.46
- VKTX 40.23
- Support Level
- RHI $36.07
- VKTX $24.77
- Resistance Level
- RHI $37.22
- VKTX $26.65
- Average True Range (ATR)
- RHI 1.09
- VKTX 1.78
- MACD
- RHI 0.32
- VKTX -0.98
- Stochastic Oscillator
- RHI 66.03
- VKTX 20.19
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.